With a number of GLP-1 medications in Phase 2 trials, we believe that the winning formula to stand out in a crowded landscape will be to combine medication with advanced behavior change to drive differentiated outcomes, while proving it with Phase 4 studies
Genetic markers in GLP1R, GIPR, FTO, and MC4R can reveal how your body is likely to respond to GLP-1 signaling and metabolic shifts
GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
We hope that this work will help us understand why these receptors work differently to each other, why they have different strengths at triggering the release of insulin and glucagon, and how changes in the genes that code for them modify the way they work in specific people.
For clinicians and researchers in India, especially in Mumbai, it offers a promising pathway toward metabolic health innovation
Inulin, and possibly other fermentable carbohydrates, could therefore represent a potentially effective intervention at the population level
